Business Context and Reporting Period
West Pharmaceutical Services, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2020. West manufactures containment, packaging, delivery systems and contract-manufactured devices for biologic, generic, pharmaceutical, diagnostic and medical-device customers. Reportable segments are Proprietary Products and Contract-Manufactured Products.
Manufacturing operations generally continued during the quarter despite COVID-19, with enhanced safety measures. Management stated that the pandemic did not significantly affect first-quarter results, but future effects remained uncertain.
Key Financial Metrics
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Net sales | $491.5 million | $443.5 million | +10.8% |
| Gross profit | $167.0 million | $146.8 million | +13.8% |
| Gross margin | 34.0% | 33.1% | +0.9 percentage points |
| Operating profit | $88.0 million | $70.7 million | +24.5% |
| Operating margin | 17.9% | 15.9% | +2.0 percentage points |
| Net income | $74.3 million | $55.4 million | +34.1% |
| Diluted EPS | $0.99 | $0.73 | +35.6% |
| Cash flow from operations | $57.1 million | $47.6 million | +$9.5 million |
| Capital expenditures | $32.1 million | $28.8 million | +$3.3 million |
Proprietary Products sales were $373.5 million, up 9.7% reported and 11.8% organically. Contract-Manufactured Products sales were $118.1 million, up 14.5% reported and 15.9% organically. Growth was led by high-value components, Daikyo and other proprietary products, and healthcare-related injection and diagnostic devices.
Proprietary Products gross margin increased to 40.2% from 38.9%; Contract-Manufactured Products gross margin increased to 14.3% from 14.0%. Management attributed margin improvement to price increases, favorable product mix and production efficiencies.
The effective tax rate declined to 17.4% from 23.1%, primarily because of higher tax deductions related to stock-based compensation. The tax benefit from stock-based compensation was $5.1 million, compared with $1.4 million in the prior-year quarter.
Financial Position, Liquidity and Debt
- Cash and cash equivalents were $335.3 million at March 31, 2020, down from $439.1 million at December 31, 2019.
- Working capital was $633.1 million, compared with $717.1 million at year-end 2019.
- Total debt was $256.7 million, including $254.4 million of long-term debt. The $300.0 million revolving credit facility had $297.5 million available, including $2.5 million of letters of credit, and had no outstanding borrowings.
- Management stated that the company was in compliance with its debt covenants and expected cash, operating cash flow and credit availability to satisfy foreseeable liquidity needs.
- Net cash used in financing activities was $120.3 million, primarily reflecting $115.5 million spent to repurchase 761,500 shares and $11.8 million of dividends.
- Cash used in investing activities was $31.9 million, principally capital expenditures.
Material Changes Versus the Prior Comparable Period
- Sales growth accelerated across both segments, with consolidated organic sales growth of 12.7% excluding foreign exchange and the 2019 acquisition.
- Operating profit increased substantially because of higher sales, improved gross margins and operating leverage, despite unfavorable foreign-currency translation of approximately $2.6 million.
- Net income benefited from the lower effective tax rate and higher operating profit.
- Foreign currency translation produced a $47.3 million pretax-free reduction in other comprehensive income, contributing to a $42.7 million decline in total other comprehensive income and reducing total equity.
- SG&A increased 4.7% to $71.8 million, while SG&A as a percentage of sales improved to 14.6% from 15.5%.
- No restructuring charges were recorded in Q1 2020, compared with $0.6 million in Q1 2019. The 2018 restructuring plan was considered complete as of December 31, 2019, although $0.8 million of severance obligations remained at March 31, 2020.
- A $1.4 million pension settlement charge was recorded in Q1 2020.
- The company adopted the current expected credit loss standard and other accounting guidance; management reported no material impact, apart from a $0.1 million cumulative-effect adjustment to retained earnings.
Guidance, Outlook, Commentary and Risks
The filing does not provide a specific quantitative full-year sales or earnings outlook. Management described liquidity and capital resources as strong and expected operations, capital expenditures and scheduled debt payments to be adequately funded.
COVID-19 remained the principal new risk factor. Potential effects include employee illness, supply-chain and transportation disruptions, restricted access to raw materials, changing customer demand and increased precautionary costs. Management could not predict the duration or ultimate financial impact of the pandemic.
Other material risks include foreign-exchange volatility, dependence on certain suppliers and partners, commodity costs for petroleum-derived elastomers, customer product approvals and commercialization, competition, pricing pressure, production efficiency, skilled-labor availability and global healthcare legislation.
The company continues to face contingencies associated with ordinary-course product liability matters and other legal proceedings. Management stated that no current proceedings were expected to have a material adverse effect, and the filing reported no significant changes to previously disclosed commitments and contingencies.
The Vial2Bag voluntary recall remained a historical unusual item. Q1 2019 included a $4.5 million provision related to returned inventory; no comparable provision was reported in Q1 2020. The company continued efforts to return the product to market.
Important Facts for Investors to Verify
- Whether COVID-19 subsequently affected customer demand, production capacity, suppliers, transportation or costs after March 31, 2020.
- Whether the strong organic sales growth and gross-margin improvement continued beyond the first quarter.
- The sustainability of the unusually favorable 17.4% effective tax rate and the $5.1 million stock-compensation tax benefit.
- The effect of foreign-currency movements on sales, margins, comprehensive income and equity.
- The company’s continued share-repurchase activity and resulting cash balance, share count and capital allocation.
- Progress and potential valuation changes related to the SmartDose platform, including the $3.2 million contingent consideration liability.
- Future capital expenditures, debt maturities and use of the $297.5 million revolving-credit capacity.
- Potential changes in demand, supply-chain resilience and regulatory or commercialization timelines for customer products.